Hepatocellular Carcinoma: Practical Implications of Emerging Data

EP. 1: Incidence of Liver Cancer in the US

July 13th 2020

EP. 2: Surveillance for Hepatocellular Carcinoma

July 13th 2020

EP. 3: Hepatocellular Carcinoma: Diagnostic Work-Up

July 13th 2020

EP. 4: Locoregional and Systemic Therapy for HCC

July 13th 2020

EP. 5: Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma

July 13th 2020

EP. 6: IO and VEGF Inhibition in Hepatocellular Carcinoma

July 13th 2020

EP. 7: HCC: Treating Patients With Atezolizumab/Bevacizumab

July 13th 2020

EP. 8: Immunotherapy in Liver Cancer

July 13th 2020

EP. 9: Novel Combinations to Treat HCC

July 13th 2020

EP. 10: Second-Line Treatment for Hepatocellular Carcinoma

July 13th 2020

EP. 11: Selecting Second-Line Therapy for HCC

July 13th 2020

EP. 12: Regorafenib or Cabozantinib for Second-Line HCC

July 13th 2020

EP. 13: Sequencing of Novel Therapies in HCC

July 13th 2020

EP. 14: Safety Profiles of Novel Therapies for HCC

July 13th 2020

EP. 15: HCC: Liver Function and Treatment Decisions

July 13th 2020

EP. 16: Emerging Biomarkers in Hepatocellular Carcinoma

July 13th 2020

EP. 17: Combination Regimens for HCC Treatment

July 13th 2020

EP. 18: HCC: Emerging Therapies Under Investigation

July 13th 2020

EP. 19: HCC: Applying Recent Data Into Practice

July 13th 2020